Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Certain proteins involved in DNA modification may affect the genetic changes in systemic lupus erythematosus and could indicate the disease's activity.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.

Hair loss in lupus patients indicates higher disease activity.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

Myositis in lupus patients is linked to skin rash, hair loss, blood issues, and high disease activity.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

Hair loss in systemic lupus erythematosus patients is unique and improves with treatment.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

Tph cells are linked to the severity of systemic lupus erythematosus.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

SLE patients experience two patterns of non-inflammatory symptoms: intermittent and persistent.

Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.

Certain KIR genes in Indian SLE patients are linked to disease severity and could be biomarkers.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

NKG2D gene polymorphism doesn't affect SLE risk but may influence symptoms like rash and hair loss.

Most lupus patients in the study experienced hair loss, which greatly affected their mental and social well-being.

Both patients and physicians are often dissatisfied with the control of systemic lupus erythematosus and lupus nephritis.

Use antimalarials like hydroxychloroquine for cutaneous lupus, avoid herbal supplements, and focus on lifestyle changes like sun protection.